Antonella Castagna
Expertise in
15
conditions

Antonella Castagna

Milan, IT 
Expertise in
15
conditions
Milan, IT 

Overview

Antonella Castagna practices practicing medicine in Milan, Italy.

Ms. Castagna is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, COVID-19, Monkeypox, Pancreaticoduodenectomy, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 535 peer reviewed articles and participating in 6 clinical trials.

Gender

Female

Locations

Milan, Italy
Other Locations
Via Diotisalvi 2, Pisa, 56122, Italy
Vita, Italy
Via Fratelli Cervi, Segrate, 20090, Italy
Verona, Italy
Rome, Italy
Florence, 50144, Italy
Turin, Italy
Rozzano, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Biktarvy, Symtuza
Study Phase: Phase 3
A Descriptive, Prospective, Multi-country, Multicentre Study to Assess Performance of Genital Herpes Simplex Virus-2 (HSV-2) Related Disease Endpoints Based on Patient-reported Health Outcomes, Self-swabbing Collected Via Decentralised Approach in Patients ≥ 18 Years of Age in the United States and Europe.
A Descriptive, Prospective, Multi-country, Multicentre Study to Assess Performance of Genital Herpes Simplex Virus-2 (HSV-2) Related Disease Endpoints Based on Patient-reported Health Outcomes, Self-swabbing Collected Via Decentralised Approach in Patients ≥ 18 Years of Age in the United States and Europe.
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Procedure
Bone Health in Aging HIV Infected Women: Improvement or Prevention of Changes in Bone Mineral Density by Switching Antiretroviral Agents. Is There an Optimal Time to Intervene?
Bone Health in Aging HIV Infected Women: Improvement or Prevention of Changes in Bone Mineral Density by Switching Antiretroviral Agents. Is There an Optimal Time to Intervene?
Enrollment Status: Completed
Publish Date: December 19, 2024
Intervention Type: Drug
Study Drugs: tenofovir-alafenamide-emtricitabine, tenofovir-emtricitabine
Study Phase: Phase 4
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drugs: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir
Study Phase: Phase 2
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3
A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects
A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects
Enrollment Status: Completed
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

534 Total Publications

Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine.
Well-being in people with HIV after one year of long-acting cabotegravir and rilpivirine.
Journal: AIDS care
Published: September 07, 2026

Frequently Asked Questions about Antonella Castagna

Is Antonella Castagna a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Antonella Castagna is classified as an Elite expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Antonella Castagna participate in research or clinical trials?

Yes. Antonella Castagna has published 534 articles and abstracts on conditions like HIV/AIDS. You can view a list of Antonella Castagna's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Castagna's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 69 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile